Integrated population pharmacokinetics and multi-omics technology to individualize tigecycline usage

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058536

Enrollment

Unknown

Registered

2022-04-10

Start date

2022-07-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe infection

Interventions

case series:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Inpatients receiving tigacycline in our hospital; 2. Intravenous tegacycline >=3 days; 3. Blood concentration monitoring of tigacycline was performed.

Exclusion criteria

Exclusion criteria: Lack of clinical data.

Design outcomes

Primary

Measure	Time frame
Blood coagulation index;Tegacycline plasma concentration;	—

Secondary

Measure	Time frame
Liver function index;Liver function index;Blood routine index;	—

Countries

China

Contacts

Public ContactWang Min

Gulou Hospital Affiliated to School of Medicine of Nanjing University

wangmin19881013@126.com+86 15051872754

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026